Hundreds of children in England prescribed weight-loss jabs

Recent figures indicate that hundreds of children in England are being prescribed GLP-1 medications, a class of drugs originally developed for type 2 diabetes that have gained widespread popularity as weight-loss aids. While the use of these drugs is often discussed in the context of adult health, investigation reveals that a significant number of children are now receiving these treatments, with some patients being under the age of 12. This trend of a "hundred England" prescriptions highlights the growing intersection of pharmaceutical intervention and childhood obesity management.

Data obtained from the NHS Business Services Authority shows that during the 2025-26 financial year, 419 prescriptions were issued to individuals under 18, with 10 of those patients being under 12. Furthermore, in the four-month period between April and July of this year, 341 prescriptions were provided to children, 15 of whom were under 12. It is important to note that these figures likely represent an underestimate, as they do not account for private prescriptions, hospital-based dispensing, or prison settings.

Hundreds of children in England are receiving GLP-1 weight-loss prescriptions, necessitating rigorous clinical oversight.

Clinical oversight and guidelines

Experts emphasize that while these drugs are effective, they must be administered within specialist services that provide comprehensive support for nutrition, mental health, and growth monitoring. Professor Martin Whyte of the University of Surrey noted that because weight often returns after medication is stopped, long-term lifestyle planning is essential. He also highlighted the limited data available regarding the long-term effects of these drugs on developing young people.

Clinicians at Complications from Excess Weight (CEW) clinics, which were piloted by the NHS to support children with severe obesity, report that these medications are typically reserved for cases where standard therapies have failed to yield results. Often, these children suffer from secondary comorbidities such as type 2 diabetes or liver disease. Although the World Health Organization recently advised against using obesity medications for children under 10, some researchers are exploring the potential for expanding usage to younger age groups as clinical evidence evolves.

Why it matters

The rising reliance on pharmaceutical interventions for childhood obesity reflects a global health challenge, with the World Health Organization reporting that 400 million children and adolescents were overweight in 2024. This trend underscores the importance of balancing effective medical treatment with the need for long-term health monitoring and the avoidance of social stigma regarding weight management.